Constipation on semaglutide

How common, and against what

Look at the two OZEMPIC rows. The higher dose produced the lower rate, which is the opposite of what nausea does on the same table, where 15.8% at 0.5 mg becomes 20.3% at 1 mg. A reaction that does not track the dose is not behaving like the ones that do, and neither label comments on it. The OZEMPIC table in full shows the contrast row by row.²

Notice also how high placebo runs. Eleven percent of people injecting salt water in the WEGOVY trials reported constipation, so a good part of what happens on this drug would have happened anyway. The honest size of the drug’s own contribution is the gap.¹

Why it feels different: it lasts

The pooled analysis of the 2.4 mg trials put a number on every effect’s episode length, and constipation is the outlier by a distance: a median of 47 days, against eight days for nausea, three for diarrhea and two for vomiting. In the same trials the placebo median was 35 days.³

That 35 matters as much as the 47. Constipation is slow to resolve in general, drug or no drug, so the drug moved a long thing somewhat longer rather than creating a long thing. Both numbers are medians: half of episodes were shorter and half ran on past them.

New episodes also stop appearing earlier than the rest. In the pooled trials constipation reaches a plateau by about week 10, while nausea, diarrhea and vomiting are still peaking around week 20. The week-by-week page has that shape for all four.³

What the labels do and do not say about it

They count it, they group it with the rest of the gut, and they give one instruction for a dose that is not tolerated:

What they do not do is tell you how to treat it. No fiber, fluid or laxative recommendation appears in either label’s adverse-reaction section, and nothing in the documents this site holds tests one on this drug, so nothing is recommended here either. That is a prescriber’s question, and it is a short one to ask.

The labels do warn about the severe end of the gut generally: severe gastrointestinal reactions were reported in 4.1% of people on WEGOVY injection against 0.9% on placebo, and WEGOVY is not recommended in patients with severe gastroparesis.¹

Eating, and the rest of the weeks

What changes about eating on this drug, and what people adjust after a step up, is on what to eat on semaglutide. If the question underneath this one is whether the whole stretch is normal, the nausea page is about where in the schedule you are. The guide to staying at a lower Wegovy dose explains the label’s flexibility without choosing a dose for you.

Questions